Categories Health Care, U.S. Markets News

CVS’ stock gains as company lays out growth strategy

CVS Health’s (NYSE: CVS) shares were up 3.2% in afternoon hours as the company outlined its growth strategy and reaffirmed guidance at its 2019 Investor Day. CVS aims to simplify the consumer health system and drive long-term growth while enhancing shareholder value.

CVS will focus on differentiating its businesses by bringing in innovative benefit designs and reimbursement models, and will work on the expansion of HealthHUBs. The company plans to open HealthHUBs in a number of cities including Houston and Atlanta. By the end of 2021, CVS intends to have a total of 1,500 HealthHUBs in operation.

CVS’ other goals include the introduction of new products and services as well as the creation of a strong technology infrastructure. The company expects to generate approx. $300-350 million of synergies from the Aetna integration in 2019 and approx. $800 million in 2020.

CVS reaffirmed its guidance for full-year 2019. The company expects consolidated revenues to come in the range of $251.2 billion to $254.4 billion. On a GAAP basis, operating income is expected to be $11.8 billion to $12 billion and on an adjusted basis, operating income is expected to be $15 billion to $15.2 billion.

GAAP diluted EPS is projected to be $4.90 to $5.05 while adjusted EPS is estimated to be $6.75 to $6.90. CVS expects to achieve adjusted EPS of at least $7.00 in 2020, mid-single digit percent adjusted EPS growth in 2021, and low double digit percent growth in 2022 and beyond.

Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips.

Most Popular

CVX Earnings: Chevron reports lower revenue and profit for Q1 2024

Energy exploration company Chevron Corporation (NYSE: CVX) announced first-quarter 2024 financial results, reporting a decline in net profit and revenues. Net income attributable to Chevron Corporation was $5.50 billion or

ABBV Earnings: AbbVie reports lower adj. profit for Q1 2024; revenue edges up

Specialty biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) Friday announced first-quarter 2024 financial results, reporting a decline in adjusted earnings and a modest rise in revenues. The company reported worldwide net

CL Earnings: Key quarterly highlights from Colgate-Palmolive’s Q1 2024 financial results

Colgate-Palmolive Company (NYSE: CL) reported first quarter 2024 earnings results today. Net sales increased 6.2% year-over-year to $5.06 billion. Organic sales increased 9.8%. Net income attributable to Colgate-Palmolive Company was

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top